Screener
MoonLake Immunotherapeutics MLTX Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebt.
The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 8:55 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001821586-26-000007
| (in thousands, except share and per share data) | March 31, 2026 (Unaudited) | December 31, 2025 |
|---|---|---|
| Short-term portion of operating lease liabilities | 920 | 1,234 |
| Total current liabilities | 46,114 | 45,478 |
| Non-current liabilities | ||
| Long-term debt | 99,018 | 74,100 |
| Long-term portion of operating lease liabilities | 865 | 374 |
| Pension liability | 353 | — |
| Total non-current liabilities | 100,236 | 74,474 |
| Total liabilities | 146,350 | 119,952 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is MoonLake Immunotherapeutics's long-term debt?
- MoonLake Immunotherapeutics (MLTX) reported long-term debt of $99.02M in Q1 2026.
- How has MoonLake Immunotherapeutics's long-term debt changed year-over-year?
- MoonLake Immunotherapeutics's long-term debt increased by 35.6% year-over-year, from $73.02M to $99.02M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about MoonLake Immunotherapeutics's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude